StrokeCN-NINMNCT06386510
Cranial Nerve Neuromodulation to Improve Arm Function and Brain Plasticity in Stroke
A study testing Strength training and Cranial nerve non-invasive neuromodulation in people with Stroke, run by Université de Sherbrooke at 3 sites in Canada.
Trial summary
Following a stroke, persistent residual muscle weakness in the upper limb (UL) drastically impacts the individuals' quality of life and level of independence. Training interventions are recommended to promote UL motor recovery, and recent studies have shown that training must be tailored to each individual's recovery… Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Stroke
- What is being tested?
- Strength training and Cranial nerve non-invasive neuromodulation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 74 participants
- Where
- 3 sitesCanada
- Study dates
- 2 Jun 2025to 1 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- be ≥18 years of age;
- have had a unilateral supratentorial stroke;
- be in a chronic stage of recovery (>6 months);
- present some UL motor recovery (Fugl-Meyer Stroke Assessment [FMA-UE] score ≥25/66);
- are not involved in rehabilitation treatments.
Who cannot join
- significant spasticity at UL (score >3 on the modified Ashworth scale);
- major sensory deficit at UL (a score <25/34 on the Nottingham sensory assessment and a score <6 on the vibration threshold assessment);
- hemineglect (> 70% of unshaded lines on the same side as the motor deficit on the Line Cancellation test);
- apraxia (score >2.5 on the Alexander test);
- a neurological disorder other than stroke-related;
- orthopedic problems at UL;
Show all 10Show fewer
- cognitive impairment (score <2/5 on the Mini-Cog);
- significant pain intensity at UL (a score ≥ 6/10 on the Visual Analog Pain Scale);
- absence of MEP (peak-to-peak MEP amplitude <20μV);
- contraindications to CN-NINM and TMS.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Canada3 sites, 3 recruiting
- Recruiting
CRIR/Feil/Oberfeld Research Center; Centre intégré de santé et de services sociaux de Laval; Jewish Rehabilitation Hospital
Laval, Quebec, H7V 1R2
Marie-Helene Boudrias, PhD, 514-398-5457, mh.boudrias@mcgill.ca
Marie-Helene Boudrias, PhD
- Recruiting
CIRRIS
Québec, Quebec, G1M2S8
Andréanne Blanchette, PhD, 418-529-9141 ext. 46896, andreanne.blanchette@fmed.ulaval.ca
Andréanne Blanchette, PhD
- Recruiting
Centre de recherche sur le vieillissement
Sherbrooke, Quebec, J1H 4C4
Marie-Helene Milot, PhD, 819-780-2220 ext. 45277, marie-helene.milot@usherbrooke.ca
Maureen Ahiatsi, MsC, 819-780-2220 ext. 45691, maureen.rudy.sandra.ahiatsi@usherbrooke.ca
About this study
Official title: Can Stimulating the Tongue Help Improve Upper Limb Motor Function and Brain Plasticity in Individuals at the Chronic Stage of a Stroke: a Randomized Controlled Trial
Following a stroke, persistent residual muscle weakness in the upper limb (UL) drastically impacts the individuals' quality of life and level of independence. Training interventions are recommended to promote UL motor recovery, and recent studies have shown that training must be tailored to each individual's recovery potential to maximise training gains. Complementary to training interventions, non-invasive brain stimulation devices (NIBS) can help support the provision of post-stroke care by modulating brain excitability and enhancing recovery. Among NIBS, cranial nerve non-invasive neuromodulation (CN-NINM) is gaining increasing attention in rehabilitation since it can directly and non-invasively stimulate the tongue's cranial nerves. The impulses generated can then reach the motor cortex, induce neuroplastic changes and support recovery. Promising results in various neurological populations have been observed, but in stroke, the efficacy of CN-NINM at improving arm motor recovery and brain plasticity is yet to be determined. This is what the present project intends to address, using a stratified randomized controlled trial, where participants in the chronic phase of a stroke will take part in a 4-week individualized training program of their affected UL in combination with real or sham CN-NINM. Before and after the intervention, participants will undergo clinical and neurophysiological evaluations to thoroughly evaluate CN-NINM-induced changes in UL motor function and associated neuroplastic changes. The proposed study will allow an in-depth evaluation of the effects of CN-NINM for an eventual implementation in clinics and at home to support optimal post-stroke recovery.
Read the detailed description
Residual muscle weakness in the affected upper limb (UL) has a significant negative impact on the performance of activities of daily living (ADL) of individuals with a stroke. Studies report that the degree of UL weakness is strongly correlated to the level of functioning in ADL, thus affecting the overall level of independence post-stroke.
Motor recovery post-stroke is mainly associated with the central nervous system's ability to reorganize, or neuroplasticity. Neuroplasticity can be assessed with non-invasive transcranial magnetic stimulation (TMS). TMS allows for assessing the excitability of the descending corticospinal pathway, the main motor pathway controlling movements of the limbs and trunk. The amplitude of TMS-elicited motor evoked potentials (MEP) gives a direct measure of the excitability of corticospinal neurons and studies have shown that MEP amplitudes can be used to probe neuroplastic changes associated with motor recovery and are good predictors of an individual response to exercise post-stroke. In a recent study on UL exercises in chronic stroke survivors, baseline MEP amplitudes were used to estimate participants' potential for recovery and to tailor the intensity of the UL training program accordingly. By stratifying them based on their MEP amplitudes, all participants, regardless of their level of post-stroke recovery, showed significant improvements in UL function following their tailored training program. Collectively, these results suggest that assessing MEP amplitude can provide an efficient way to evaluate neuroplasticity as well as to assist in staging and tailoring individuals' training intervention to optimize post-stroke recovery.
To enhance neuroplasticity, training exercises are critical to rehabilitation post-stroke since they allow for improvement in UL motor function and strength as well as promote brain plasticity, leading to increased use of the UL in ADLs. To capitalize on the benefit of strength training at promoting motor recovery and neuroplasticity, non-invasive brain neurostimulation (NIBS) modalities are increasingly studied as an adjunct therapy in stroke rehabilitation. To date, transcranial direct current stimulation (tDCS) is the most studied NIBS, but a great variability in response to tDCS is noted, with more than 50% of individuals not responding as expected. This heterogeneity across studies in tDCS response could be explained by the absence of a consensus on optimal stimulation parameters, the influence of individual brain anatomical characteristics on the response to tDCS and the presence of an electric current shunting through the skull. Thus, to counteract the impact of inter-individual anatomical variability and electrical current shunting by the skull, recent studies are now investigating cranial nerve stimulation as an adjunct therapy in stroke when paired with rehabilitation. An emerging NIBS therapeutic device, stimulating two major cranial nerves, the trigeminal and glossopharyngeal nerves, by tongue stimulation, is making its way into neurological rehabilitation, that is cranial nerve non-invasive neuromodulation (CN-NINM). By applying electrodes directly to the tongue, CN-NINM allows the generation of a direct flow of neural impulses that travel to the cranial nerve nuclei of the brainstem and then to the motor cortex to induce targeted neuroplastic changes when combined with rehabilitation treatments. Following various neurological injuries and combined with many interventions, CN-NINM results in improved functional performance such as walking and balance. Neuroplasticity changes have also been observed such as an increase in the brain beta activation measured with electroencephalography and increased activation in the primary motor cortex area. Post-stroke, only one study has compared the impact of CN-NINM combined with a 2-week balance and gait training program (experimental group) to a 2-week balance and gait training program alone (control group) on functional performance, as assessed with the Mini-Best test, in individuals in the subacute stage of a stroke. Based on Mini-Best test score, an improvement in balance in the experimental group compared with the control group was noted (p=0.032). Although promising, CN-NINM has not been studied to improve UL function, despite the negative impact of UL impairment on post-stroke functional performance. Also, to lay the foundation for the applicability of this NIBS in stroke, understanding the neurophysiological effects of CN-NINM by evaluating neuroplasticity changes is crucial.
Objective: The main objective is to assess the impact of CN-NINM combined with a tailored UL strength training program on improvement in UL function and brain excitability in individuals at the chronic stage of a stroke. The secondary objective is to assess the presence of a relationship between UL functional gain and change in brain excitability for the study sample.
Methods: In this multicentered stratified randomized controlled trial, 74 participants will be recruited and stratified according to the baseline amplitude of their TMS-induced MEP responses into three strata of training intensity: 1) low-intensity (MEP 20-49μV); 2) moderate-intensity (MEP 50-120uV) and 3) high-intensity (MEP>120uV). . Within each stratum, participants will be randomized into the experimental group (real CN-NINM + UL strength training) or the control group (sham CN-NINM + UL strength training). Sociodemographic and stroke-related variables (e.g., age, time since stroke) will be collected to confirm participant eligibility. Prior to and at the end of the intervention, participants will undergo a clinical evaluation of their affected UL as well as a neurophysiological brain evaluation with TMS. The intervention will consist of a 4-week UL strength training program (3X/week, 60-minute duration) combined to a 20-minute CN-NINM application. For the experimental group, the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink. For the control group, participants will wear the device such as the experimental group, but the intensity will be controlled by the trainer and set to a non-perceivable stimulus.
- Conditions
- Stroke
- Being tested
- Strength training, Cranial nerve non-invasive neuromodulation
- Keywords
- Cranial nerve non-invasive neuromodulation, Brain plasticity, Recovery, Strength training, Transcranial magnetic stimulation
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Strength trainingProcedure or surgery
The strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM for the wrist extensors and the elbow and shoulder flexors. The grip muscles of the affected hand will also be trained with a JAMAR® dynamometer. Depending on each participant's intensity training group, training will start at 35%, 50% or 70% of 1RM and will be increased by 5% each week to reach, by week 4, 50%, 65% and 85%, for the low, moderate, and high-intensity group, respectively.
Cranial nerve non-invasive neuromodulationProcedure or surgery
For the first 20 minutes of each training session, CN-NINM will be applied (50 μsec at 150 Hz), using a portable stimulator (Cthulhu Shield, USA) with a network of 18 electrodes, directly on the participants' tongue. The participants will hold the device in place by pressing their tongue upwards and the intensity of the stimulus will be set by each participant to a comfortable level of sensation (experimental group) or set by a trainer to a non-perceivable stimulus (control group).
| Study group | Role | What they receive |
|---|---|---|
| real CN-NINM + UL training group | Experimental | Upper limb strength training program combined to real CN-NINM Receives: Procedure: Strength training; Procedure: Cranial nerve non-invasive neuromodulation |
| sham CN-NINM + UL training group | Placebo comparator | Upper limb strength training program combined to sham CN-NINM Receives: Procedure: Strength training; Procedure: Cranial nerve non-invasive neuromodulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in UL motor function on the Fugl-Meyer Stroke Assessment Scale
Change in motor function of the affected UL will be assessed using the Fugl-Meyer Stroke Assessment. The score of this scale range from 0 (no motor recovery) to 66 (full motor recovery).
Measured: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM
Change in UL functional performance on the Wolf Motor Function Test
Change in functional performance of the affected UL will be assessed with the timed score of the Wolf Motor Function Test; comprising 17 tasks. The maximal time allocated to each task is 120 seconds.
Measured: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Change in motor cortex excitability by means of resting MEP amplitudes elicited by TMS over both hemispheres.
Change in motor cortex excitability will be assessed by resting peak-to-peak MEP amplitudes of the affected and unaffected first dorsal interosseous muscles (FDI) at 130% of the FDI resting motor threshold over 20 trials
Measured: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Secondary outcomes (3)
Change in participants' subjective real life functional UL performance on the Motor Activity Log
Change in participants' self-reported affected UL performance in everyday activities will be assessed with the Motor Activity Log (MAL). The MAL comprises 14 task scored on a 0 to 5 Likert scale, where a score of 5 represents normal quantity and quality of use of affected UL.
Measured: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Change in active and passive range of motion at both UL in shoulder flexion, elbow flexion and wrist extension
Change in active and passive range of motion at both UL will be assessed in degrees with a manual goniometer
Measured: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Change in resting motor threshold of the affected and unaffected FDI
Change in resting motor threshold of the affected and unaffected FDI will be assessed with TMS and described as % of output stimulator
Measured: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2024
- Study start2 Jun 2025
- Primary completion1 Aug 2027 (estimated)
- Study completion1 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- More trials run by Université de SherbrookeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- multicentered stratified randomized controlled trial
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 74 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université de Sherbrooke
- Sponsor type
- University, hospital or other
- Collaborators
- Heart and Stroke Foundation of Canada
- Responsible party
- Sponsor
- Investigators
- Marie-Helene Milot, PhD, Principal investigator, Université de Sherbrooke
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06386510
- Sponsor's protocol ID
- 2025-5517
- Acronym
- CN-NINM
- Status last verified
- May 2026
- First submitted
- 23 Apr 2024
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can Stimulating the Tongue Help Improve Upper Limb Motor Function and Brain Plasticity in Individuals at the Chronic Stage of a Stroke: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06386510
- Acronym / sponsor ID
- CN-NINM / 2025-5517
- Conditions
- Stroke
- Keywords
- Cranial nerve non-invasive neuromodulation, Brain plasticity, Recovery, Strength training, Transcranial magnetic stimulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 74 participants (estimated)
- Lead sponsor
- Université de SherbrookeUniversity, hospital or other
- Collaborators
- Heart and Stroke Foundation of Canada
- Study start
- 2 Jun 2025 (actual)
- Primary completion
- 1 Aug 2027 (estimated)
- Study completion
- 1 Aug 2027 (estimated)
- First posted
- 26 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Following a stroke, persistent residual muscle weakness in the upper limb (UL) drastically impacts the individuals' quality of life and level of independence. Training interventions are recommended to promote UL motor recovery, and recent studies have shown that training must be tailored to each individual's recovery potential to maximise training gains. Complementary to training interventions, non-invasive brain stimulation devices (NIBS) can help support the provision of post-stroke care by modulating brain excitability and enhancing recovery. Among NIBS, cranial nerve non-invasive neuromodulation (CN-NINM) is gaining increasing attention in rehabilitation since it can directly and non-invasively stimulate the tongue's cranial nerves. The impulses generated can then reach the motor cortex, induce neuroplastic changes and support recovery. Promising results in various neurological populations have been observed, but in stroke, the efficacy of CN-NINM at improving arm motor recovery and brain plasticity is yet to be determined. This is what the present project intends to address, using a stratified randomized controlled trial, where participants in the chronic phase of a stroke will take part in a 4-week individualized training program of their affected UL in combination with real or sham CN-NINM. Before and after the intervention, participants will undergo clinical and neurophysiological evaluations to thoroughly evaluate CN-NINM-induced changes in UL motor function and associated neuroplastic changes. The proposed study will allow an in-depth evaluation of the effects of CN-NINM for an eventual implementation in clinics and at home to support optimal post-stroke recovery.
Detailed description
Residual muscle weakness in the affected upper limb (UL) has a significant negative impact on the performance of activities of daily living (ADL) of individuals with a stroke. Studies report that the degree of UL weakness is strongly correlated to the level of functioning in ADL, thus affecting the overall level of independence post-stroke.
Motor recovery post-stroke is mainly associated with the central nervous system's ability to reorganize, or neuroplasticity. Neuroplasticity can be assessed with non-invasive transcranial magnetic stimulation (TMS). TMS allows for assessing the excitability of the descending corticospinal pathway, the main motor pathway controlling movements of the limbs and trunk. The amplitude of TMS-elicited motor evoked potentials (MEP) gives a direct measure of the excitability of corticospinal neurons and studies have shown that MEP amplitudes can be used to probe neuroplastic changes associated with motor recovery and are good predictors of an individual response to exercise post-stroke. In a recent study on UL exercises in chronic stroke survivors, baseline MEP amplitudes were used to estimate participants' potential for recovery and to tailor the intensity of the UL training program accordingly. By stratifying them based on their MEP amplitudes, all participants, regardless of their level of post-stroke recovery, showed significant improvements in UL function following their tailored training program. Collectively, these results suggest that assessing MEP amplitude can provide an efficient way to evaluate neuroplasticity as well as to assist in staging and tailoring individuals' training intervention to optimize post-stroke recovery.
To enhance neuroplasticity, training exercises are critical to rehabilitation post-stroke since they allow for improvement in UL motor function and strength as well as promote brain plasticity, leading to increased use of the UL in ADLs. To capitalize on the benefit of strength training at promoting motor recovery and neuroplasticity, non-invasive brain neurostimulation (NIBS) modalities are increasingly studied as an adjunct therapy in stroke rehabilitation. To date, transcranial direct current stimulation (tDCS) is the most studied NIBS, but a great variability in response to tDCS is noted, with more than 50% of individuals not responding as expected. This heterogeneity across studies in tDCS response could be explained by the absence of a consensus on optimal stimulation parameters, the influence of individual brain anatomical characteristics on the response to tDCS and the presence of an electric current shunting through the skull. Thus, to counteract the impact of inter-individual anatomical variability and electrical current shunting by the skull, recent studies are now investigating cranial nerve stimulation as an adjunct therapy in stroke when paired with rehabilitation. An emerging NIBS therapeutic device, stimulating two major cranial nerves, the trigeminal and glossopharyngeal nerves, by tongue stimulation, is making its way into neurological rehabilitation, that is cranial nerve non-invasive neuromodulation (CN-NINM). By applying electrodes directly to the tongue, CN-NINM allows the generation of a direct flow of neural impulses that travel to the cranial nerve nuclei of the brainstem and then to the motor cortex to induce targeted neuroplastic changes when combined with rehabilitation treatments. Following various neurological injuries and combined with many interventions, CN-NINM results in improved functional performance such as walking and balance. Neuroplasticity changes have also been observed such as an increase in the brain beta activation measured with electroencephalography and increased activation in the primary motor cortex area. Post-stroke, only one study has compared the impact of CN-NINM combined with a 2-week balance and gait training program (experimental group) to a 2-week balance and gait training program alone (control group) on functional performance, as assessed with the Mini-Best test, in individuals in the subacute stage of a stroke. Based on Mini-Best test score, an improvement in balance in the experimental group compared with the control group was noted (p=0.032). Although promising, CN-NINM has not been studied to improve UL function, despite the negative impact of UL impairment on post-stroke functional performance. Also, to lay the foundation for the applicability of this NIBS in stroke, understanding the neurophysiological effects of CN-NINM by evaluating neuroplasticity changes is crucial.
Objective: The main objective is to assess the impact of CN-NINM combined with a tailored UL strength training program on improvement in UL function and brain excitability in individuals at the chronic stage of a stroke. The secondary objective is to assess the presence of a relationship between UL functional gain and change in brain excitability for the study sample.
Methods: In this multicentered stratified randomized controlled trial, 74 participants will be recruited and stratified according to the baseline amplitude of their TMS-induced MEP responses into three strata of training intensity: 1) low-intensity (MEP 20-49μV); 2) moderate-intensity (MEP 50-120uV) and 3) high-intensity (MEP>120uV). . Within each stratum, participants will be randomized into the experimental group (real CN-NINM + UL strength training) or the control group (sham CN-NINM + UL strength training). Sociodemographic and stroke-related variables (e.g., age, time since stroke) will be collected to confirm participant eligibility. Prior to and at the end of the intervention, participants will undergo a clinical evaluation of their affected UL as well as a neurophysiological brain evaluation with TMS. The intervention will consist of a 4-week UL strength training program (3X/week, 60-minute duration) combined to a 20-minute CN-NINM application. For the experimental group, the intensity of the stimulus will be set by each participant to a comfortable level of sensation, similar to the sensation in the mouth of a soft drink. For the control group, participants will wear the device such as the experimental group, but the intensity will be controlled by the trainer and set to a non-perceivable stimulus.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- multicentered stratified randomized controlled trial
| Arm | Type | Receives |
|---|---|---|
| real CN-NINM + UL training group | Experimental | Procedure: Strength training, Procedure: Cranial nerve non-invasive neuromodulationUpper limb strength training program combined to real CN-NINM |
| sham CN-NINM + UL training group | Placebo comparator | Procedure: Strength training, Procedure: Cranial nerve non-invasive neuromodulationUpper limb strength training program combined to sham CN-NINM |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- be ≥18 years of age;
- have had a unilateral supratentorial stroke;
- be in a chronic stage of recovery (>6 months);
- present some UL motor recovery (Fugl-Meyer Stroke Assessment [FMA-UE] score ≥25/66);
- are not involved in rehabilitation treatments.
Key exclusion criteria (10 listed)
- significant spasticity at UL (score >3 on the modified Ashworth scale);
- major sensory deficit at UL (a score <25/34 on the Nottingham sensory assessment and a score <6 on the vibration threshold assessment);
- hemineglect (> 70% of unshaded lines on the same side as the motor deficit on the Line Cancellation test);
- apraxia (score >2.5 on the Alexander test);
- a neurological disorder other than stroke-related;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Strength trainingThe strength training program will last 4 weeks (3 X/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM for the wrist extensors and the elbow and shoulder flexors. The grip muscles of the affected hand will also be trained with a JAMAR® dynamometer. Depending on each participant's intensity training group, training will start at 35%, 50% or 70% of 1RM and will be increased by 5% each week to reach, by week 4, 50%, 65% and 85%, for the low, moderate, and high-intensity group, respectively. | Procedure or surgery | real CN-NINM + UL training group, sham CN-NINM + UL training group |
| Cranial nerve non-invasive neuromodulationFor the first 20 minutes of each training session, CN-NINM will be applied (50 μsec at 150 Hz), using a portable stimulator (Cthulhu Shield, USA) with a network of 18 electrodes, directly on the participants' tongue. The participants will hold the device in place by pressing their tongue upwards and the intensity of the stimulus will be set by each participant to a comfortable level of sensation (experimental group) or set by a trainer to a non-perceivable stimulus (control group). | Procedure or surgery | real CN-NINM + UL training group, sham CN-NINM + UL training group |
Primary outcome
Change in UL motor function on the Fugl-Meyer Stroke Assessment Scale
Time frame: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM
Change in motor function of the affected UL will be assessed using the Fugl-Meyer Stroke Assessment. The score of this scale range from 0 (no motor recovery) to 66 (full motor recovery).
Change in UL functional performance on the Wolf Motor Function Test
Time frame: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Change in functional performance of the affected UL will be assessed with the timed score of the Wolf Motor Function Test; comprising 17 tasks. The maximal time allocated to each task is 120 seconds.
Change in motor cortex excitability by means of resting MEP amplitudes elicited by TMS over both hemispheres.
Time frame: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Change in motor cortex excitability will be assessed by resting peak-to-peak MEP amplitudes of the affected and unaffected first dorsal interosseous muscles (FDI) at 130% of the FDI resting motor threshold over 20 trials
3 secondary outcomes
Change in participants' subjective real life functional UL performance on the Motor Activity Log
Time frame: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Change in active and passive range of motion at both UL in shoulder flexion, elbow flexion and wrist extension
Time frame: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Change in resting motor threshold of the affected and unaffected FDI
Time frame: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
Related trials for Stroke
Not yet recruiting
Foot Drop Rehabilitation and Mobility in Chronic Stroke
Stroke
Enrolling by invitation
Study on the Efficacy and Safety of Non-Invasive Brain-Computer Interface With MRI-Guided Multi-Channel Time-Domain Interference Stimulation in Treating Motor Dysfunction in Acute Cerebral Infarction Patients
Acute Ichemic Stroke
RecruitingObservational study
Development, Validation and Normative Data of the Italian Battery for the Recognition of Famous Faces (FAME)
Stroke, Alzheimer s Disease
Enrolling by invitation
Long-Term Clinical, Health Economic, and Process Evaluation of Intensive Technology-Integrated Motor Rehabilitation in Chronic Neurological Conditions (INTeRAcT-bis)
Stroke, Spinal Cord Injuries (SCI)
Not yet recruitingPhase 2
Rimonabant for Improving Walking Ability in Patients With Chronic Stroke
Chronic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marie-Helene Milot, PhD principal investigator
Université de Sherbrooke
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Strength training and Cranial nerve non-invasive neuromodulation in people with Stroke, run by Université de Sherbrooke at 3 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marie-Helene Milot, PhD (819-780-2220 ext. 45277, marie-helene.milot@usherbrooke.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in UL motor function on the Fugl-Meyer Stroke Assessment Scale (time frame: The assessments will be done at the baseline and in the week after completion of the training program and CN-NINM). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.